Abiopharma

🔍 Zook Anthony P. (Director)

Company: NEOGENOMICS INC (NEO)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 140,498 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 178,564.00 | transaction_form_type: 4
• Sold 45,453 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 133,111.00 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: H | nature_of_ownership: Amended and Restated Anthony P. Zook Living Trust | shares_owned_after: 18,900.00
• Sold 140,498 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 280,998.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 8,353 shares of Stock Option (Right to Buy) at $14.82 per share (Derivative)
  Date: 2026-04-01 | Code: H | Expires: 2033-08-10 | Exercise: 2024-08-10 | shares_owned_after: 8,353.00
• Holds 8,672 shares of Stock Option (Right to Buy) at $13.71 per share (Derivative)
  Date: 2026-04-01 | Code: H | Expires: 2034-06-01 | Exercise: 2025-06-01 | shares_owned_after: 8,672.00
• Holds 729,927 shares of Stock Option (Right to Buy) at $10.44 per share (Derivative)
  Date: 2026-04-01 | Code: H | Expires: 2035-04-01 | shares_owned_after: 729,927.00 | Footnotes: F3, F4
• Holds 675,676 shares of Stock Option (Right to Buy) at $10.81 per share (Derivative)
  Date: 2026-04-01 | Code: H | Expires: 2036-03-01 | shares_owned_after: 675,676.00 | Footnotes: F5, F6
• Holds 406,918 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: H | shares_owned_after: 406,918.00 | Footnotes: F7, F2

Footnotes:

• F1: On April 1, 2025, Mr. Zook was granted 421,496 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
• F2: Once vested, the shares of common stock are not subject to expiration.
• F3: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on April 1, 2025 and multiplied by 110%.
• F4: On April 1, 2025, Mr. Zook was granted 729,927 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F5: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
• F6: On March 1, 2026, Mr. Zook was granted 675,676 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F7: On March 1, 2026, Mr. Zook was granted 406,918 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.